US Army Medical Research and Materiel Command

Slides:



Advertisements
Similar presentations
Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
Advertisements

MICROSPHERES AS A NOVEL DRUG DELIVERY SYSTEM Omkar. T, Vikas College of Pharmacy, Vissannapet, Andhrapradesh For more presentations and information visit.
Applications of Nanoparticles for Delivery of Therapeutic Agents Frank Jeyson Hernández Topics of Nanobiotechnology 30 June, 2004.
Protein Modifications -- to increase stability.
1 Controlled Release Introduction and Background.
Overview  Founded in 2008  Privately held technology development company  Reorganized under new ownership as Tamarisk Technologies Group in 2014 About.
About Microbionical About Founded Business idea: Commercialize Seek & Heal™ technology. ACO Läkemedel, Stockholm – pharmaceutical development.
Introducing Apceden™.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
The Pharmaceutical Composition Methodology described in this presentation has been developed to improve controlled drug delivery through site specific.
Naked DNA By Amber Spiering, Amit Khosla, Jason Powell, Liz Viola, Dan Poor, Lisa Smith.
Entrepreneurial Track, “Developing Your Product” Target Product Profiles Medical & Development Considerations and Challenges Barbara Wirostko, M.D.,
Concepts and Applications of Pharmacokinetics
NANOTECHNOLOGIES: THE NEW GENERATION OF MEDICINE Dr Mariano Licciardi.
Nanotechnology in Cancer Treatment
1.  Drug delivery is the method or process of administering pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Most common.
Liposomes Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Enteric-coated alendronate sodium solid lipid nanoparticles; a novel formula to overcome barriers for the treatment of osteoporosis By Funded Project.
Technology Available for Licensing US Army Medical Research and Materiel Command A Pharmaceutical Composition Containing pGLU- GLU-PRO-NH 2 and Methods.
The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.
DELIVERY OF PROTEINS USING BIODEGRADABLE POLYMERS Mahesh V. Chaubal Guilford Pharmaceuticals Inc. Baltimore, MD 21224
Intellectual Property Rights and Pharmaceutical Industry
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
The Pharmaceutical Composition Methodology described in this presentation has been developed to improve controlled drug delivery through site specific.
Technology Available for Licensing US Army Medical Research and Materiel Command Recombinant Vaccine Against Botulinum Neurotoxin This invention provides.
Abstract Polymeric Porous microspheres are an effective drug delivery mechanism able to control drug release, preventing drug wastage and lowering costs.
Pharmaceutical Composition Claims and Enablement Robert J. Hill, Jr. Quality Assurance Specialist Technology Center
Modular Nanodevices for Creation of Smart Adaptable Vaccine Delivery Vehicles Tarek M. Fahmy Dept. of Biomedical Engineering, Yale University Several key.
School of Pharmacy - The University of Auckland Formulation and Drug Delivery Research Theme School of Pharmacy, the University of Auckland, Auckland,
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Design of Sustained Release Dosage Forms
 Introduction  What is polymer?  Classification on the basis of various types  Natural polymer  Biodegradable polymer  Characteristics of ideal.
Polymer1 Poly (L-lacitde)/Poly (1,5- dioxepan-2-one) Blends in Drug Release Device Maggie Wang October 27, 2000 The main article came from Journal of.
Principles and methods of vaccine production and fish immunization
Cost effectively maximizing oral bioavailability of existing and emerging drug technologies through better drug delivery design. Tamarisk’s Value Statement.
LOCAL DRUG DELIVERY SYSTEM INTRODUCTION  Periodontal disease is associated with bacteria and treatment by chemotherapeutic agents appears to be appropriate.
ColoPlus – benefits by value adding
Elizabeth Herlihy, BSN, MS NYSDOH Immunization Program
INNOVATION IN THE DEVELOPMENT OF NEW DRUGS AND CREATIVE SOLUTIONS TO ENSURING EARLY AND ENHANCED ACCESS Paul Stoffels, M.D. Chief Scientific Officer,
One DES Eluting Two Drugs: Is it Feasible?
Biopharmaceutics of modified release drug products
Interpenetrating Networks for Delivery Systems
Novel Drug Delivery System
Anthrax immune globulin human
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
From Bench to Clinical Applications: Money Talks
Dr Paul T Francis, MD Community Medicine College of Medicine, Zawia
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
Firdaus | Sofia | Nurainiza | Hafizah
US Army Medical Research and Materiel Command
Advancing the Treatment of IBD With Biologics
Drug Delivery Systems Pharmaceutical technology Petra University.
US Army Medical Research and Materiel Command
Reverse Vaccinology: Developing Vaccines in the Era of Genomics
How to Manage ISRs That Occur With Injectable Agents in Psoriasis
ColoPlus – benefits by value adding
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
Seminar Date : October 23 (Weds.) 2019, 15:00 ~ 18:00 Venue : Engineering Building 2 (25314) Speaker : Prof. Tong-Fei Shi State Key Laboratory of Polymer.
Presentation transcript:

US Army Medical Research and Materiel Command Technology Available for Licensing Therapeutic Treatment and Prevention of Infections with Bioactive Materials Encapsulated within a Biodegradable-Biocompatible Polymeric Matrix Features and advantages: • Optimal drug release due to capped status and blend ratio of terminal carboxyl ends within PLGA • Biodegradable, antibiotic-releasing microspheres more effective than standard therapy in eliminating osteomyelitis • Encapsulated hepatitis B antigen is as immunogenic as the conventional vaccine • GI administered CFA/II pilus vaccine, stabilized within microspheres, elicited protective immunity in vivo This invention is a process to prepare sustained release, burst-free, biodegradable microspheres that deliver pharmaceuticals, antigens, and bioactive agents. The blend ratio of end-capped to uncapped (free carboxyl ends) of the poly(lactide/glycolide) [PLGA] copolymer was found key to the exquisite control and duration of release achieved. Antibiotics (ampicillin, cefazolin), vaccine antigens (hepatitis B and CFA/II pilus vaccine), and a representative polypeptide (histatin) were encapsulated.  After sustained in vitro drug release was obtained for each formulation, they were evaluated for efficacy in vivo. A single dose application of antibiotic microspheres was as effective as a 14 day standard course of systemic antibiotic in preventing soft tissue infections, and the single dose encapsulated drug was more effective than standard therapy in eliminating osteomyelitis. Intraduodenal administration of encapsulated E. coli CFA/II pilus vaccine was safe and immunogenic in eliciting protective immunity. Encapsulated hepatitis B antigen produced an immunity equivalent to conventional Heptavax B vaccine in mice. These studies confirm the power of sustained drug delivery in achieving diverse and heightened biological effects in the delivery of pharmaceuticals, vaccine antigens, and bioactive agents in vivo. Advantages accrued from developing this technology include reduced drug toxicity, stabilization of labile agent in vivo, conservation of precious agent, single dose therapy, targeted drug delivery, and ease of use. Patent Status Patent No.: 6,844,010 Date Issued: January 18, 2005 Available from: www.uspto.gov Docket No.: WRAIR 01-06 Point of Contact Dr. Paul C. Mele Director, Office of Research and Technology Applications USAMRMC, MCMR-ZA-J 504 Scott St., Ft. Detrick, MD 21702-5012 E-mail: usamrmcorta@amedd.army.mil Voice: 301-619-6664/2065/7219 Fax: 301-619-5034 KEYWORDS: pharmaceuticals; sustained release; drug delivery; vaccines Licensing Opportunities • Patent licenses are available to companies with commercial interests